meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
5
es-BC - TNBC - NA - PDL1 positive
1
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
1
mBC - TNBC - L1 - all population
7
mBC - TNBC - L1 - PDL1 positive
4
mBC-Triple negative (TNBC) - 2nd Line (L2)
3
mBC - TNBC - L2 - all population
2
mBC - TNBC - L2 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus nab-paclitaxel
atezolizumab plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age > 65y
Asian type
ECOG 0
ECOG 1
metastasis (bone)
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
metastasis (lung)
metastasis (lymph node )
stage III (locally advanced)
stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
deaths (OS)
mBC - TNBC - L1 - PDL1 positive
breast cancer - triple negative
mBC - Triple negative (TNBC) - 1st Line (L1)
mBC - TNBC - L1 - PDL1 positive
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC)
1
1.0
better
0.3
5.0
99 %
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open